Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, ...
Medical Dialogues

Insulin Injections Linked to Rare Amyloid Masses in a 40-Year-Old Woman, Case Report Warns

The report highlights that insulin-derived amyloidosis can mimic other injection-site reactions and should be considered when ...
Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...
Medscape

Woman on Insulin Develops Injection-Site Amyloidosis

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.

BLA for subcutaneous formulation of Leqembi® accepted in China

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
Nasdaq

Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...